Skip to main content
. 2022 Apr-Jun;15(2):135–141. doi: 10.4103/JCAS.JCAS_1_21

Table 3.

Drop-outs from the study

Reason for drop-outs Group
Total
A B
No improvement (%) 3 (8.6%) 0 (0%) 3 (1.5%)
Side effects (%) 1 (2.9%) 2 (6.1%) 3 (2.3%)
Worsening of lesions (%) 2 (5.7%) 0 (0%) 2 (0.8%)
Loss to follow-up (%) 0 (0%) 1 (3.0%) 1 (1.5%)
Total (%) 35 (100.0%) 33 (100.0%) 68 (100.0%)